Predictors of Treatment Failure in Children With HIV Starting First-line Antiretroviral Therapy in the ODYSSEY Trial
Clinical Infectious Diseases · 2026
DOI: 10.1093/cid/ciag232 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Clinical Infectious Diseases, 2026. Verfasst von James Wyncoll und 25 weiteren Autor:innen. Beteiligte Einrichtung: UCL Innovative Clinical Trials Unit (formerly the MRC Clinical Trials Unit at UCL, until March 2026), Institute of Clinical Trials and Methodology, L…. Hauptthemen laut MEDLINE: HIV Infections, Heterocyclic Compounds, 3-Ring, Anti-HIV Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Penta Foundation, ViiV Healthcare and UK Medical Research Council, ViiV Healthcare and Mylan-Viatris.
Themen: Kinderkrankenpflege
Abstract (Originalsprache)
Background
Data on predictors of treatment failure in children starting antiretroviral therapy (ART) are limited, particularly on dolutegravir-based regimens (DTG).
Methods
ODYSSEY demonstrated superior efficacy of DTG versus standard-of-care (SOC). We assessed predictors at ART initiation of treatment failure by 96 weeks.
Results
Three hundred and eighty-one children started first-line ART (82% African). At ART-initiation, median age was 10.5 years (IQR: 6.5, 14.0, 67 < 3 years), CD4% 20% (IQR: 12, 28), BMI-for-age Z-score –.58 (IQR:–1.48, +.25). One hundred and eighty-nine children started DTG, 192 started SOC (91% ≥3 years started efavirenz; 79% <3 years started lopinavir). Seventy-five children experienced treatment failure (24 DTG, 51 SOC). Failure risk was lower on DTG than SOC (hazard ratio [HR] = 0.47, 95% CI: 0.29–0.77, P = .002). Lower BMI-for-age Z-score (HR = 0.82 for each unit gain, 95% CI: 0.70–0.96, P = .01) and being at an African site (HR = 2.09, 95% CI: 0.82–5.31, P = .09) were associated with higher failure risk. Risk was also higher at younger ages with the steepest increase in the youngest children and increased at lower CD4%, with a stronger CD4% effect at younger ages. At CD4% = 20, HRs relative to age 10 years were 2.40 (95% CI: 1.58–3.65) at age 1 year, 1.30 (95% CI: 1.15–1.48) at age 5 years, and 0.80 (95% CI: 0.72–0.89) at age 18 years. At age 1 year, HRs relative to CD4% = 20 were 1.39 (95% CI: 1.16–1.66) at CD4% = 15, and 0.52 (95% CI: 0.36–0.75) at CD4% = 30; at age 10, corresponding estimates were 1.07 (95% CI: 0.94–1.20) at CD4% = 15, and 0.88 (95% CI: 0.69–1.13) at CD4% = 30.
Conclusions
Young age, low BMI-for-age, and low CD4% at ART initiation predicted higher risk of treatment failure and can guide targeted support.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- UCL Innovative Clinical Trials Unit (formerly the MRC Clinical Trials Unit at UCL, until March 2026), Institute of Clinical Trials and Methodology, London, United Kingdom.
- Department of Pediatrics, Nakornping Hospital, Chiang Mai, Thailand.
- Department of Paediatrics, Enhancing Care Foundation, Victoria Mxenge Hospital, Durban, South Africa.
- Child Adolescent and Women's Health Department, University of Zimbabwe Clinical Research Centre, Harare, Zimbabwe.
- Department of Research, Baylor College of Medicine Children's Foundation, Kampala, Uganda.
- Perinatal HIV Research Unit, University of the Witwatersrand, Johannesburg, South Africa.
ORCID-Profile: James Wyncoll, Mark Cotton, Laura Marques, Pablo Rojo, Diana M Gibb
Förderung
- Penta Foundation
- ViiV Healthcare and UK Medical Research Council
- ViiV Healthcare and Mylan-Viatris
- ODYSSEY trial
Zitieren
APA
Wyncoll, J., Kamolrattana, R., Archary, M., Mujuru, H. A., Kekitiinwa, A. R., Violari, A., Na-Rajsima, S., Lugemwa, A., Variava, E., Cotton, M., Kityo, C. M., Königs, C., Behuhuma, N. O., Welch, S., Saïdi, Y., Marques, L., Ahimbisibwe, G. M., Houlden, L., Giaquinto, C., …, & ODYSSEY Trial Team (2026). Predictors of Treatment Failure in Children With HIV Starting First-line Antiretroviral Therapy in the ODYSSEY Trial. Clinical Infectious Diseases. https://doi.org/10.1093/cid/ciag232
Vancouver
Wyncoll J, Kamolrattana R, Archary M, Mujuru HA, Kekitiinwa AR, Violari A, et al. Predictors of Treatment Failure in Children With HIV Starting First-line Antiretroviral Therapy in the ODYSSEY Trial. Clinical Infectious Diseases. 2026. doi:10.1093/cid/ciag232
BibTeX
@article{Wyncoll2026,
author = {Wyncoll, James and Kamolrattana, Rujirek and Archary, Moherndran and Mujuru, Hilda A and Kekitiinwa, Adeodata R and Violari, Avy and Na-Rajsima, Sathaporn and Lugemwa, Abbas and Variava, Ebrahim and Cotton, Mark and Kityo, Cissy M and Königs, Christoph and Behuhuma, Ngundu Osee and Welch, Steven and Saïdi, Yacine and Marques, Laura and Ahimbisibwe, Grace M and Houlden, Lily and Giaquinto, Carlo and Rojo, Pablo and Gibb, Diana M and Puthanakit, Thanyawee and Turkova, Anna and White, Ellen and Ford, Deborah and ODYSSEY Trial Team, ODYSSEY Trial Team},
title = {Predictors of Treatment Failure in Children With HIV Starting First-line Antiretroviral Therapy in the ODYSSEY Trial},
journal = {Clinical Infectious Diseases},
year = {2026},
doi = {10.1093/cid/ciag232}
}
EUVIMED